GeNO LLC Announces Senior Management Appointments

              GeNO LLC Announces Senior Management Appointments

PR Newswire

WALTHAM, Mass., Dec. 18, 2012

Dasse named President; Gellman named Senior Vice President, Engineering

WALTHAM, Mass., Dec. 18, 2012 /PRNewswire/ --GeNO LLC, a privately held
pharmaceutical company that is developing innovative nitric oxide (NO)
generation and delivery platforms, today announced that Kurt Dasse, a member
of the company's Board of Managers and formerly Executive Vice President, has
been appointed President of GeNO. Prior to joining GeNO, he served as
President and CEO of Waltham, Massachusetts based technology company
Levitronix LLC.

In addition, Barry Gellman has been appointed Senior Vice President,
Engineering, to focus on GeNO's research, development, and production.

"These appointments will help provide a strong foundation as we continue to
develop and deliver innovative, cost-effective nitric oxide generation and
delivery platforms for the treatment of multiple diseases and conditions,"
said David Fine, GeNO Founder, Chairman and CEO. "We have already realized
significant milestones under Kurt's leadership. His vast experience in
conducting research in cardiovascular disorders and developing medical devices
has been invaluable. Barry's capabilities in developing ventricular assist
devices combined with his extensive engineering and management expertise help
to position GeNO very well for the future."

Dasse, who will continue to serve on the Company's Board of Managers, has
spent nearly 30 years researching cardiovascular disorders and developing
medical devices, including products to treat heart and renal failure. He
joined GeNO as a member of the Board of Managers in 2007 and as Executive Vice
President in 2011. Dasse founded Levitronix LLC in 2001 as the Chief Technical
Officer, and became President & CEO in 2006. Earlier in his career, Dasse was
Chief Scientist and Vice President of $700-million Thermo Electron
Corporation's biomedical group. He also was one of the founding officers of
Thermo Cardiosystems and played a key role in commercializing the first
implantable ventricular assist system for end-stage heart-failure patients.
Dasse received his doctorate in medical physiology from Boston University and
his bachelor's degree in biology from the University of Massachusetts. He has
written more than 100 journal articles and multiple book chapters, and holds
numerous patents.

Gellman has devoted his 38 year career to biomedical engineering and
management roles within several companies. At GeNO, Gellman will manage all
research, development and production functions. He joins GeNO from Thoratec
Corporation. He spent seven years as Vice President of Engineering in the
medical division of Levitronix. In these roles, Gellman was responsible for
engineering, management and strategic planning for mechanical circulatory
support devices, including ventricular assist devices (VAD) and extracorporeal
membrane oxygenator systems (ECMO). Gellman was Director of Research and
Development and Chief Engineer of the urology and gynecology division for
Boston Scientific Corporation, among other management roles during his 13
years with the company. Gellman received his Master of Science in mechanical
engineering from the New Jersey Institute of Technology and his Bachelor of
Science in the same discipline from the Newark College of Engineering.
Gellman's extensive patent experience includes 90 US patents issued on his
work, and 123 patent pending applications.

GeNO LLC, founded in 2006, is a privately held pharmaceutical company that is
developing innovative nitric oxide (NO) generation and delivery platforms to
enable the true potential of inhaled nitric oxide to be realized for the
treatment of a multitude of diseases. The company is focused on applying its
technology to delivering inhaled NO to patients in a variety of settings,
including ambulatory and in-home use for potential chronic treatment. GeNO
will provide stand-alone medical devices and combination products that include
delivery systems and GeNO's nitric oxide gas. GeNO's nitric oxide delivery
systems have been designated as combination products by the Food and Drug
Administration (FDA) Office of Combination Products, with the Division of
Cardiovascular and Renal Products designated as the lead reviewer. The
combination products will be regulated by the FDA as new drugs with their own
new drug applications.

Media Contacts:
Kellie Caldwell, 610-505-1511

Brian Heffron, 781-799-9568


Press spacebar to pause and continue. Press esc to stop.